Table 2. Immunosuppressive/DMARD (disease modifying anti-rheumatic drugs) therapies received before belimumab in patients not IS-naïve (n=80).
| Drug | Patients (%) |
| Azathioprine (%) | 29 (36) |
| Mycophenolate (%) | 23 (29) |
| Methotrexate (%) | 39 (49) |
| Cyclophosphamide (%) | 15 (19) |
| Cyclosporine (%) | 20 (25) |
| Other (%) | 4 (5) |
ISimmunosuppressants